|
1
|
Du Bois A and Pfisterer J: Future options
for first-line therapy of advanced ovarian cancer. Int J Gynecol
Cancer. 15 (Suppl 1):S42–S50. 2005. View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 95 (Suppl
1):S161–S192. 2006. View Article : Google Scholar
|
|
4
|
Dodge JE, Covens AL, Lacchetti C, Elit LM,
Le T, Devries-Aboud M and Fung-Kee-Fung M; Gynecology Cancer
Disease Site Group, : Preoperative identification of a suspicious
adnexal mass: A systematic review and meta-analysis. Gynecol Oncol.
126:157–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim
S, Jung YW, Kim SW and Kim YT: Diagnosis and staging of primary
ovarian cancer: Correlation between PET/CT, Doppler US, and CT or
MRI. Gynecol Oncol. 116:389–394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Buamah P: Benign conditions associated
with raised serum CA-125 concentration. J Surg Oncol. 75:264–265.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Buys SS, Partridge E, Black A, Johnson CC,
Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B,
et al: Effect of screening on ovarian cancer mortality: The
prostate, lung, colorectal and ovarian (PLCO) cancer screening
randomized controlled trial. JAMA. 305:2295–2303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj
A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E,
Cruickshank D, et al: Ovarian cancer screening and mortality in the
UK collaborative trial of ovarian cancer screening (UKCTOCS): A
randomized controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Horiuchi K, Yonekawa O, Iwahara K, Kanno
T, Kurihara T and Fujise Y: A hydrophilic tetrahydro-beta-carboline
in human urine. J Biochem. 115:362–366. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gutsche B, Grun C, Scheutzow D and
Herderich M: Tryptophan glycoconjugates in food and human urine.
Biochem J. 343:11–19. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hofsteenge J, Müller DR, de Beer T,
Löffler A, Richter WJ and Vliegenthart JF: New type of linkage
between a carbohydrate and a protein: C-glycosylation of a specific
tryptophan residue in human RNase Us. Biochemistry. 33:13524–13530.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Furmanek A and Hofsteenge J: Protein
C-mannosylation: Facts and questions. Acta Biochim Pol. 47:781–789.
2000.PubMed/NCBI
|
|
13
|
Shcherbakova A, Tiemann B, Buettner FF and
Bakker H: Distinct C-mannosylation of netrin receptor
thrombospondin type 1 repeats by mammalian DPY19L1 and DPY19L3.
Proc Natl Acad Sci USA. 114:2574–2579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Buettner FF, Ashikov A, Tiemann B, Lehle L
and Bakker H: C. Elegans DPY-19 is a C-mannosyltransferase
glycosylating thrombospondin repeats. Mol Cell. 50:295–302. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Niwa Y, Suzuki T, Dohmae N and Simizu S:
Identification of DPY19L3 as the C-mannosyltransferase of
R-spondin1 in human cells. Mol Biol Cell. 27:744–756. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ihara Y, Inai Y, Ikezaki M, et al:
C-Mannosylation: Modification on tryptophan in celluar proteins.
Taniguchi N, Endo T, Hart GW, et al: Glycoscience, biology and
medicine. 2. Springer; Japan: pp. 1091–1099. 2015, View Article : Google Scholar
|
|
17
|
Sekula P, Dettmer K, Vogl FC, Gronwald W,
Ellmann L, Mohney RP, Eckardt KU, Suhre K, Kastenmüller G, Oefner
PJ and Köttgen A: From discovery to translation: Characterization
of C-mannosyltryptophan and pseudouridine as markers of kidney
function. Sci Rep. 7:174002017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takahira R, Yonemura K, Yonekawa O,
Iwahara K, Kanno T, Fujise Y and Hishida A: Tryptophan
glycoconjugate as a novel marker of renal function. Am J Med.
110:192–197. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yonemura K, Takahira R, Yonekawa O, Wada N
and Hishida A: The diagnostic value of serum concentrations of
2-(alpha- mannopyranosyl)-L-tryptophan for normal renal function.
Kidney Int. 65:1395–1399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Niewczas MA, Sirich TL, Mathew AV, Skupien
J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J, et
al: Uremic solutes and risk of end-stage renal disease in type 2
diabetes: Metabolomic study. Kidney Int. 85:1214–1224. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Solini A, Manca ML, Penno G, Pugliese G,
Cobb JE and Ferrannini E: Prediction of declining renal function
and albuminuria in patients with type 2 diabetes by metabolomics. J
Clin Endocrinol Metab. 101:696–704. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mizuta H, Kuga K, Suzuki T, Niwa Y, Dohmae
N and Simizu S: C-mannosylation of R-spondin2 activates
Wnt/β-catenin signaling and migration activity in human tumor
cells. Int J Oncol. 54:2127–2138. 2019.PubMed/NCBI
|
|
23
|
Li Y, Cao C, Jia W, Yu L, Mo M, Wang Q,
Huang Y, Lim JM, Ishihara M, Wells L, et al: Structure of the
F-spondin domain of mindin, an integrin ligand and pattern
recognition molecule. EMBO J. 28:286–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simon I, Liu Y, Krall KL, Urban N, Wolfert
RL, Kim NW and McIntosh MW: Evaluation of the novel serum markers
B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of
ovarian cancer. Gynecol Oncol. 106:112–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sakurai S, Inai Y, Minakata S, Manabe S,
Ito Y and Ihara Y: A novel assay for detection and quantification
of C-mannosyl tryptophan in normal or diabetic mice. Sci Rep.
9:46752019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Manabe S and Ito Y: Total synthesis of
novel subclass of Glyco- amino acid structure motif:
C2-α-D-C-Mannosyl-L-tryptophan. J Am Chem Soc. 121:9754–9755. 1999.
View Article : Google Scholar
|
|
27
|
Burger RA, Brady MF, Bookman MA, Fleming
GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE,
et al: Incorporation of bevacizumab in the primary treatment of
ovarian cancer. N Engl J Med. 365:2473–2483. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ledermann J, Harter P, Gourley C,
Friedlander M, Vergote I, Rustin G, Scott CL, Meier W,
Shapira-Frommer R, Safra T, et al: Olaparib maintenance therapy in
patients with platinum-sensitive relapsed serous ovarian cancer: A
preplanned retrospective analysis of outcomes by BRCA status in a
randomized phase 2 trial. Lancet Oncol. 15:852–861. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Menon U, Talaat A, Rosenthal AN, Macdonald
ND, Jeyerajah AR, Skates SJ, Sibley K, Oram DH and Jacobs IJ:
Performance of ultrasound as a second line test to serum CA125 in
ovarian cancer screening. BJOG. 107:165–169. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rocconi RP, Matthews KS, Kemper MK,
Hoskins KE, Huh WK and Straughn JM Jr: The timing of normalization
of CA-125 levels during primary chemotherapy is predictive of
survival in patients with epithelial ovarian cancer. Gynecol Oncol.
114:242–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Drescher CW, Shah C, Thorpe J, O'Briant K,
Anderson GL, Berg CD, Urban N and McIntosh MW: Longitudinal
screening algorithm that incorporates change over time in CA125
levels identifies ovarian cancer earlier than a single-threshold
rule. J Clin Oncol. 31:387–392. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Menon U, Gentry-Maharaj A, Hallett R, Ryan
A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, et
al: Sensitivity and specificity of multimodal and ultrasound
screening for ovarian cancer, and stage distribution of detected
cancers: Results of the prevalence screen of the UK Collaborative
trial of ovarian cancer screening (UKCTOCS). Lancet Oncol.
10:327–340. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Adamczyk B, Tharmalingam T and Rudd PM:
Glycans as cancer biomarkers. Biochim Biophys Acta. 1820:1347–1353.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Anugraham M, Jacob F, Everest-Dass AV,
Schoetzau A, Nixdorf S, Hacker NF, Fink D, Heinzelmann-Schwarz V
and Packer NH: Tissue glycomics distinguish tumour sites in women
with advanced serous adenocarcinoma. Mol Oncol. 11:1595–1615. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Biskup K, Braicu EI, Sehouli J, Fotopoulou
C, Tauber R, Berger M and Blanchard V: Serum glycome profiling: A
biomarker for diagnosis of ovarian cancer. J Proteome Res.
12:4056–4063. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Menni C, Kastenmüller G, Petersen AK, Bell
JT, Psatha M, Tsai PC, Gieger C, Schulz H, Erte I, John S, et al:
Metabolomic markers reveal novel pathways of ageing and early
development in human populations. Int J Epidemiol. 42:1111–1119.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lustgarten MS and Fielding RA: Metabolites
related to renal function, immune activation, and carbamylation are
associated with muscle composition in older adults. Exp Gerontol.
100:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Huang J, Weinstein SJ, Moore SC, Derkach
A, Hua X, Liao LM, Gu F, Mondul AM, Sampson JN and Albanes D: Serum
metabolomic profiling of all-cause mortality: A prospective
analysis in the alpha-tocopherol, beta-carotene cancer prevention
(ATBC) study cohort. Am J Epidemiol. 187:1721–1732. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tanizaki Y, Kobayashi A, Toujima S, Shiro
M, Mizoguchi M, Mabuchi Y, Yagi S, Minami S, Takikawa O and Ino K:
Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of
ovarian cancer by inducing an immunosuppressive environment. Cancer
Sci. 105:966–973. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schroecksnadel K, Winkler C, Fuith LC and
Fuchs D: Tryptophan degradation in patients with gynecological
cancer correlates with immune activation. Cancer Lett. 223:323–329.
2005. View Article : Google Scholar : PubMed/NCBI
|
